Cancer Research and Treatment

Original Articles

Clinical Effectiveness and Cost-Effectiveness of Robot-Assisted Versus Conventional Esophagectomy: Joon Beom Park, Myung-Il Hahm, Hong Kwan Kim, Danbee Kang, Seong Yong Park; Received October 29, 2025 Accepted June 8, 2026 Published online June 19, 2026; DOI: https://doi.org/10.4143/crt.2025.1188 [Accepted]

Abstract PDF: Purpose
This study evaluated the comparative clinical effectiveness and cost-effectiveness of robot-assisted minimally invasive esophagectomy (RAMIE) versus open esophagectomy (OE) and conventional minimally invasive esophagectomy (MIE) in a nationwide real-world setting.
Materials and Methods
A target trial emulation was conducted using the Korean National Health Insurance Service database, including patients who underwent first-time esophagectomy for esophageal cancer between 2010 and 2023, with survival followed through June 2024. Propensity score–matched cohorts were created for RAMIE versus OE (n=1,713 per group) and RAMIE versus MIE (n=1,162 per group). Clinical outcomes were compared, and a 5-year semi-Markov model was used to estimate quality-adjusted life-years (QALYs) and costs from a healthcare sector perspective with a 4.5% annual discount rate. Incremental cost-effectiveness ratios (ICERs), incremental net benefits (INBs), and probabilistic sensitivity analyses were calculated.
Results
RAMIE showed comparable or better short-term outcomes, including lower incidence of transfusion-requiring bleeding risk than OE (23.6% vs. 32.5%; relative risk [RR], 0.73; 95% CI, 0.65–0.81) and MIE (27.9% vs. 33.6%; RR, 0.88; 95% CI, 0.77–0.99). Long-term survival was superior to OE (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.72–0.88) and similar to MIE (HR, 0.93; 95% CI, 0.82–1.06). RAMIE yielded higher QALYs (Δ0.311 vs. OE; Δ0.126 vs MIE) and lower 5-year costs ($12,372–$19,765 vs. OE; $1,703–$9,097 vs. MIE), resulting in negative ICERs, positive INBs, and high probabilities of cost-effectiveness in sensitivity analyses.
Conclusion
RAMIE showed a favorable clinical and cost-effectiveness profile compared with OE and MIE, adding to the evidence base for its broader adoption.

626 View
25 Download

Gastrointestinal cancer

Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following Surgery: Won Kyung Cho, Jae Myoung Noh, Dongryul Oh, Yong Chan Ahn, Jong-Mu Sun, Hong Kwan Kim, Young Mog Shim; Cancer Res Treat. 2025;57(1):165-173. Published online July 26, 2024; DOI: https://doi.org/10.4143/crt.2024.191

Abstract PDF Supplementary Material PubReader ePub

Purpose
There is few evidence regarding the optimal salvage treatment options for loco-reginal recurrence of esophageal cancer. This study aimed to evaluate the clinical outcomes of salvage radiotherapy (RT) in patients with loco-regional recurrence (LRR) after surgery for esophageal cancer.
Materials and Methods
We retrospectively reviewed 147 esophageal cancer patients who received salvage RT for loco-regional recurrence between 1996 and December 2019. A total dose of 60 Gy in 20 fractions was used for RT alone and 60-70 Gy in 30-35 fractions for concurrent chemoradiotherapy (CCRT).
Results
The patients’ median age was 65 years (range, 41 to 86 years). The median disease-free interval was 13.5 months (1.0 to 97.4 months). After a median 18.8 months follow-up, the 2-year overall survival (OS) and progression-free survival (PFS) rates were 38.1% and 25.9%, respectively. The median OS and PFS were 18.8 and 8.4 months, respectively. The CCRT could not improve OS compared to RT (p=0.336), but there was a trend of better PFS in the CCRT group. Regarding toxicities, the rate of grade 3 or higher toxicity was 10.9% occurring in 16 patients, and it was higher in patients who received CCRT than in the RT alone group (19.6% vs. 6.3%, p=0.023).
Conclusion
Salvage RT alone as well as CCRT could be effective in patients with locoregionally recurrent esophageal cancer.

Citations

Citations to this article as recorded by

Review of Neoadjuvant Strategies in Esophageal Squamous Cell Carcinoma: JCOG1109 NExT is Here to Stay
Mayank Tripathi, Kumar Vineet
Indian Journal of Surgery.2026; 88(3): 700. CrossRef
Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba
Annals of Gastroenterological Surgery.2026;[Epub] CrossRef
Long‐Term Survival With Minimum Side‐Effects in a Post‐Op Case of Carcinoma Esophagus With Multiple Recurrences in Mediastinum Treated With Radical Re‐Radiotherapy in Mediastinum—A Case Report
Ajay Kumar Choubey, Pritam Mondal, Shubham Dokania, Sambit Swarup Nanda, Shreya Jain, Minesh Patel, Ashutosh Mukherji, Satyajit Pradhan
Clinical Case Reports.2026;[Epub] CrossRef
Chemoradiotherapy versus Chemotherapy Alone in Extensive-Stage Small Cell Esophageal Carcinoma: A Multicenter Retrospective Study Highlighting the Role of Radiotherapy (ChiSCEC)
L. Peng, J. Zhu, J. Peng, Y. Wang, H. Sun, B. Zou, Y. Zhang, N. Yang, Z. Xiao, Y. Gui, X. Su, B. Tan, J. Ma, L. Peng, W. Zhang, W. Huang, Q. Wang
Clinical Oncology.2026; 52: 104092. CrossRef
Prognosis of Isolated Cervical Node Recurrence After Esophagectomy With Two-Field Lymphadenectomy for Esophageal Squamous Cell Carcinoma
Yeong Jeong Jeon, Jeong A. Son, Junghee Lee, Seong Yong Park, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jong-Mu Sun, Sehhoon Park, Dongryul Oh, Hong Kwan Kim
The Annals of Thoracic Surgery.2026; 121(6): 1356. CrossRef
Anlotinib combined with chemoradiotherapy for postoperative isolated lymph node recurrence of ESCC: a phase II study
Jing Huang, Zhenlin Gu, Jinjing Xu, Changhua Yu, Weiguo Zhu, Yiyuan Zhang, Yong Gao
Frontiers in Immunology.2026;[Epub] CrossRef
Outcomes Of Neoadjuvant Chemoradiation Vs Neoadjuvant Chemotherapy for Esophageal Junction Signet Ring Cell Adenocarcinoma
Zamaan Hooda, Dylan Langburt, Ana McCracken, Gabriele Carbone, Shanique Ries, Mara B. Antonoff, Arlene M. Correa, Reza Mehran, Ravi Rajaram, David Rice, Stephen Swisher, Ara Vaporciyan, Garrett Walsh, Kyle G. Mitchell, Lorenzo Ferri, Wayne Hofstetter
The Annals of Thoracic Surgery.2026;[Epub] CrossRef
Salvage Chemoradiotherapy for Loco-Regional Recurrence of Esophageal Squamous Cell Carcinoma After Esophagectomy
Atsuto Katano, Tomoki Kiritoshi, Subaru Sawayanagi, Hideomi Yamashita
Journal of Clinical Medicine.2025; 14(5): 1540. CrossRef

4,651 View
123 Download
6 Web of Science
8 Crossref

Lung and Thoracic cancer

Factors Associated with Postoperative Recurrence in Stage I to IIIA Non–Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data: Kyu Yean Kim, Ho Cheol Kim, Tae Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang Gun Suh, Chang Hoon Song, Jin Seok Ahn, Jeong Eun Lee, Jae Hyun Jeon, Chi Young Jung, Jeong Su Cho, Yoo Duk Choi, Seung Sik Hwang, Chang Min Choi, Seung Hun Jang, Jeong Uk Lim, Korean Association for Lung Cancer, Korea Central Cancer Registry; Cancer Res Treat. 2025;57(1):83-94. Published online July 10, 2024; DOI: https://doi.org/10.4143/crt.2024.073

Abstract PDF Supplementary Material PubReader ePub

Purpose
Recent development in perioperative treatment of resectable non–small cell lung cancer (NSCLC) have changed the landscape of early lung cancer management. The ADAURA trial has demonstrated the efficacy of adjuvant osimertinib treatment in resectable NSCLC patients; however, studies are required to show which subgroup of patients are at a high risk of relapse and require adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment. This study evaluated risk factors for postoperative relapse among patients who underwent complete resection.
Materials and Methods
Data were obtained from the Korean Association for Lung Cancer Registry (KALC-R), a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee.
Results
A total of 3,176 patients who underwent curative resection was evaluated. The mean observation time was approximately 35.4 months. Among stage I to IIIA NSCLC patients, the EGFR-mutant subgroup included 867 patients, and 75.2%, 11.2%, and 11.8% were classified as stage I, stage II, and stage III, respectively. Within the EGFR-mutant subgroup, 44 (5.1%) and 121 (14.0%) patients showed early and late recurrence, respectively. Multivariate analysis on association with postoperative relapse among the EGFR-mutant subgroup showed that age, pathologic N and TNM stages, pleural invasion status, and surgery type were independent significant factors.
Conclusion
Among the population that underwent complete resection for early NSCLC with EGFR mutation, patients with advanced stage, pleural invasion, or limited resection are more likely to show postoperative relapse.

Citations

Citations to this article as recorded by

EGFR Mutations and Recurrence Outcomes in Resected Non‐Small Cell Lung Cancer: An Updated 2015–2025 Systematic Review and Meta‐Analysis
Soo Han Kim, Hayoung Seong, Hyojin Jang, Saerom Kim, Wanho Yoo, Jeongha Mok, Kwangha Lee, Ki Uk Kim, Min Ki Lee, Mi‐Hyun Kim, Jung Seop Eom
Thoracic Cancer.2026;[Epub] CrossRef

9,577 View
261 Download
3 Web of Science
1 Crossref

Enhancing Identification of High-Risk cN0 Lung Adenocarcinoma Patients Using MRI-Based Radiomic Features: Harim Kim, Jonghoon Kim, Soohyun Hwang, You Jin Oh, Joong Hyun Ahn, Min-Ji Kim, Tae Hee Hong, Sung Goo Park, Joon Young Choi, Hong Kwan Kim, Jhingook Kim, Sumin Shin, Ho Yun Lee; Cancer Res Treat. 2025;57(1):57-69. Published online June 26, 2024; DOI: https://doi.org/10.4143/crt.2024.251

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to develop a magnetic resonance imaging (MRI)–based radiomics model to predict high-risk pathologic features for lung adenocarcinoma: micropapillary and solid pattern (MPsol), spread through air space, and poorly differentiated patterns.
Materials and Methods
As a prospective study, we screened clinical N0 lung cancer patients who were surgical candidates and had undergone both ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET/CT) and chest CT from August 2018 to January 2020. We recruited patients meeting our proposed imaging criteria indicating high-risk, that is, poorer prognosis of lung adenocarcinoma, using CT and FDG PET/CT. If possible, these patients underwent an MRI examination from which we extracted 77 radiomics features from T1-contrast-enhanced and T2-weighted images. Additionally, patient demographics, maximum standardized uptake value on FDG PET/CT, and the mean apparent diffusion coefficient value on diffusion-weighted image, were considered together to build prediction models for high-risk pathologic features.
Results
Among 616 patients, 72 patients met the imaging criteria for high-risk lung cancer and underwent lung MRI. The magnetic resonance (MR)–eligible group showed a higher prevalence of nodal upstaging (29.2% vs. 4.2%, p < 0.001), vascular invasion (6.5% vs. 2.1%, p=0.011), high-grade pathologic features (p < 0.001), worse 4-year disease-free survival (p < 0.001) compared with non-MR-eligible group. The prediction power for MR-based radiomics model predicting high-risk pathologic features was good, with mean area under the receiver operating curve (AUC) value measuring 0.751-0.886 in test sets. Adding clinical variables increased the predictive performance for MPsol and the poorly differentiated pattern using the 2021 grading system (AUC, 0.860 and 0.907, respectively).
Conclusion
Our imaging criteria can effectively screen high-risk lung cancer patients and predict high-risk pathologic features by our MR-based prediction model using radiomics.

Citations

Citations to this article as recorded by

Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective
Jeremy J. Erasmus, Ioannis Vlahos
Journal of Thoracic Oncology.2026; 21(5): 103563. CrossRef
Equilibrium Contrastive Learning for Imbalanced Image Classification
Sumin Roh, Harim Kim, Ho Yun Lee, Il Yong Chun
IEEE Transactions on Emerging Topics in Computational Intelligence.2026; 10(3): 2429. CrossRef
Integrating CT Radiomics and Machine Learning for Preoperative Assessment of STAS Grading and Prognostic Stratification in Lung Adenocarcinoma
Qiuxing Chen, Siqi Qu, Fang Chen, Shulin Li, Zhihe Yang, Qijia Han, Zhu Ai, Peng Wang, Kun Ma, Zhiming Xiang
Academic Radiology.2026;[Epub] CrossRef

6,147 View
182 Download
2 Web of Science
3 Crossref

Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial: Junghoon Shin, Sehhoon Park, Kyung Hwan Kim, Eui-Cheol Shin, Hyun Ae Jung, Jong Ho Cho, Jong-Mu Sun, Se-Hoon Lee, Yong Soo Choi, Jin Seok Ahn, Jhingook Kim, Keunchil Park, Young Mog Shim, Hong Kwan Kim, Jae Myoung Noh, Yong Chan Ahn, Hongryull Pyo, Myung-Ju Ahn; Cancer Res Treat. 2024;56(4):1084-1095. Published online April 30, 2024; DOI: https://doi.org/10.4143/crt.2024.084

Abstract PDF Supplementary Material PubReader ePub

Purpose
Optimal treatment for stage IIIA/N2 non–small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT).
Materials and Methods
In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and safety. As an exploratory biomarker analysis, we evaluated the proliferative response of blood CD39⁺PD-1⁺CD8⁺ T cells using fold changes in the percentage of proliferating Ki-67⁺ cells from days 1 to 7 of cycle 1 (Ki-67_D7/D1).
Results
Between October 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) patients harbored EGFR and ALK alterations, respectively. Of 34 patients with programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) had a tumor proportion score of < 1%, 1%-50%, and ≥ 50%, respectively. The median follow-up was 71 months. The median DFS was 22.4 months in the overall population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% at 5 years. Patients with tumor recurrence within 6 months had a significantly lower Ki-67D7/D1 among CD39⁺PD-1⁺CD8⁺ T cells than those without (p=0.036). No new safety signals were identified.
Conclusion
Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA/N2 NSCLC patients after neoadjuvant CCRT and surgery.

Citations

Citations to this article as recorded by

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
Hong Huang, Pengchen Bao, Hongyu Jin, Wenyang Li, Hui Shen, Zhen Qin, Ying Pan, Xinming Su, Delei Kong
Frontiers in Oncology.2025;[Epub] CrossRef
Advances in molecular pathology and therapy of non-small cell lung cancer
Qing Huang, Yuanxiang Li, Yingdan Huang, Jingyi Wu, Wendai Bao, Chang Xue, Xiaoyu Li, Shuang Dong, Zhiqiang Dong, Sheng Hu
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
A retrospective analysis of neoadjuvant chemotherapy in pneumonectomy for locally advanced central non–small cell lung cancer
Yuchen Wang, Zhihang Dang, Pu Jiang, Zhifeng Li, Jin Yang, Kun Gao, Xiaona Chen, Jifang Yao
PeerJ.2025; 13: e20007. CrossRef

8,158 View
188 Download
3 Web of Science
3 Crossref

Clinical Effect of Endosonography on Overall Survival in Patients with Radiological N1 Non–Small Cell Lung Cancer: Bo-Guen Kim, Byeong-Ho Jeong, Goeun Park, Hong Kwan Kim, Young Mog Shim, Sun Hye Shin, Kyungjong Lee, Sang-Won Um, Hojoong Kim, Jong Ho Cho; Cancer Res Treat. 2024;56(2):502-512. Published online December 4, 2023; DOI: https://doi.org/10.4143/crt.2023.840

Abstract PDF Supplementary Material PubReader ePub: Purpose
It is unclear whether performing endosonography first in non–small cell lung cancer (NSCLC) patients with radiological N1 (rN1) has any advantages over surgery without nodal staging. We aimed to compare surgery without endosonography to performing endosonography first in rN1 on the overall survival (OS) of patients with NSCLC.
Materials and Methods
This is a retrospective analysis of patients with rN1 NSCLC between 2013 and 2019. Patients were divided into ‘no endosonography’ and ‘endosonography first’ groups. We investigated the effect of nodal staging through endosonography on OS using propensity score matching (PSM) and multivariable Cox proportional hazard regression analysis.
Results
In the no endosonography group, pathologic N2 occurred in 23.0% of patients. In the endosonography first group, endosonographic N2 and N3 occurred in 8.6% and 1.6% of patients, respectively. Additionally, 51 patients were pathologic N2 among 249 patients who underwent surgery and mediastinal lymph node dissection (MLND) in endosonography first group. After PSM, the 5-year OSs were 68.1% and 70.6% in the no endosonography and endosonography first groups, respectively. However, the 5-year OS was 80.2% in the subgroup who underwent surgery and MLND of the endosonography first group. Moreover, in patients receiving surgical resection with MLND, the endosonography first group tended to have a better OS than the no endosonography group in adjusted analysis using various models.
Conclusion
In rN1 NSCLC, preoperative endosonography shows better OS than surgery without endosonography. For patients with rN1 NSCLC who are candidates for surgery, preoperative endosonography may help improve survival through patient selection.

5,300 View
119 Download

Gastrointestinal cancer

Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study: Sehhoon Park, Yurimi Lee, Jiyun Lee, Yang Won Min, Hong Kwan Kim, Joon Young Choi, Hyun Ae Jung, Yong Soo Choi, Yoon-La Choi, Young Mog Shim, Jong-Mu Sun; Cancer Res Treat. 2024;56(2):567-579. Published online October 16, 2023; DOI: https://doi.org/10.4143/crt.2023.897

Abstract PDF Supplementary Material PubReader ePub

Purpose
Programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors have shown efficacy in metastatic esophageal squamous cell carcinoma (ESCC) therapy. However, data is still limited regarding neoadjuvant immunotherapy for operable ESCC.
Materials and Methods
Patients with clinical stage T2 or T3 and N0 ESCC received three cycles of nivolumab therapy every two weeks before surgical resection. The primary endpoint is major pathologic responses (MPR) rate (≤ 10% of residual viable tumor [RVT]).
Results
Total 20 patients completed the planned nivolumab therapy. Among them, 17 patients underwent surgery as protocol, showing MPR in two patients (MPR rate, 11.8%), including one pathologic complete response, on conventional pathologic response evaluation. Pathologic response was re-evaluated using the immune-related pathologic response criteria based on immune-related RVT (irRVT). Three patients were classified as immunologic major pathologic response (iMPR; ≤ 10% irRVT, iMPR rate: 17.6%), five as pathologic partial response (> 10% and < 90% irRVT), and nine as pathologic nonresponse (≥ 90% irRVT). The combined positive score (CPS) for PD-L1 in the baseline samples was predictable for iMPR, with the probability as 37.5% in CPS ≥ 10 (3/8) and 0% in CPS < 10 (0/9).
Conclusion
Although the efficacy of neoadjuvant nivolumab therapy was modest in unselected ESCC patients, further researches on neoadjuvant immunotherapy are necessary in patients with PD-L1 expressed ESCC.

Citations

Citations to this article as recorded by

Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
J.S. Deutsch, R.A. Scolyer, E. Burton, K.J. Busam, K.Y. Chen, A. Cimino-Mathews, T.R. Cottrell, C.E. de Andrea, P.O. Fiset, G.V. Long, J. Messina, R.V. Rawson, R. Salgado, C.M. Schürch, R.R. Seethala, L.M. Sholl, S. Signoretti, S.L. Topalian, B.A. van de
Annals of Oncology.2026; 37(2): 141. CrossRef
Adverse drug reaction assessment of pembrolizumab and nivolumab in esophageal cancer treatment based on the US FAERS database
Jinhan Chen, Qian Xu, Yuou Ying, Jinsheng Yu, Yi Liu, Fangmin Zhao, Qijin Shu
Frontiers in Immunology.2026;[Epub] CrossRef
Low Serum Interleukin-6 Levels Enhance the Efficacy of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
Yawei Wang, Ye Hu, Yi Qin, Xiangfeng Jin, Yandong Zhao
Cancer Biotherapy and Radiopharmaceuticals.2025; 40(10): 768. CrossRef
Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation
Yoo Kyung Choi, Seok Hyun Son, Hong Seok Jang, In-Ho Kim, Sea-Won Lee, Soo-Yoon Sung, Satyajeet Rath
PLOS One.2025; 20(11): e0336794. CrossRef

7,552 View
199 Download
5 Web of Science
4 Crossref

Lung and Thoracic cancer

Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer: Il-Hyun Park, Dae-Soon Son, Yoon-La Choi, Ji-Hyeon Choi, Ji-Eun Park, Yeong Jeong Jeon, Minseob Cho, Hong Kwan Kim, Yong Soo Choi, Young Mog Shim, Jung Hee Kang, Suzy Park, Jinseon Lee, Sung-Hyun Kim, Byung-Chul Lee, Jhingook Kim; Cancer Res Treat. 2024;56(1):81-91. Published online June 20, 2023; DOI: https://doi.org/10.4143/crt.2023.408

Abstract PDF Supplementary Material PubReader ePub

Purpose
Recently, we developed allele-discriminating priming system (ADPS) technology. This method increases the sensitivity of conventional quantitative polymerase chain reaction up to 100 folds, with limit of detection, 0.01%, with reinforced specificity. This prospective study aimed to develop and validate the accuracy of ADPS epidermal growth factor receptor (EGFR) Mutation Test Kit using clinical specimens.
Materials and Methods
In total 189 formalin-fixed paraffin-embedded tumor tissues resected from patients with non–small cell lung cancer were used to perform a comparative evaluation of the ADPS EGFR Mutation Test Kit versus the cobas EGFR Mutation Test v2, which is the current gold standard. When the two methods had inconsistent results, next-generation sequencing–based CancerSCAN was utilized as a referee.
Results
The overall agreement of the two methods was 97.4% (93.9%-99.1%); the positive percent agreement, 95.0% (88.7%-98.4%); and the negative percent agreement, 100.0% (95.9%-100.0%). EGFR mutations were detected at a frequency of 50.3% using the ADPS EGFR Mutation Test Kit and 52.9% using the cobas EGFR Mutation Test v2. There were 10 discrepant mutation calls between the two methods. CancerSCAN reproduced eight ADPS results. In two cases, mutant allele fraction was ultra-low at 0.02% and 0.06%, which are significantly below the limit of detection of the cobas assay and CancerSCAN. Based on the EGFR genotyping by ADPS, the treatment options could be switched in five patients.
Conclusion
The highly sensitive and specific ADPS EGFR Mutation Test Kit would be useful in detecting the patients who have lung cancer with EGFR mutation, and can benefit from the EGFR targeted therapy.

Citations

Citations to this article as recorded by

Highly Sensitive 3D‐Nanoplasmonic‐Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy
Ji Young Lee, Byeong‐Ho Jeong, Ho Sang Jung, Taejoon Kang, Yeonkyung Park, Jin Kyung Rho, Sung‐Gyu Park, Min‐Young Lee
Small Science.2024;[Epub] CrossRef
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer
Adam Szpechcinski, Joanna Moes-Sosnowska, Paulina Skronska, Urszula Lechowicz, Magdalena Pelc, Malgorzata Szolkowska, Piotr Rudzinski, Emil Wojda, Krystyna Maszkowska-Kopij, Renata Langfort, Tadeusz Orlowski, Pawel Sliwinski, Mateusz Polaczek, Joanna Chor
International Journal of Molecular Sciences.2024; 25(14): 7908. CrossRef

7,793 View
344 Download
2 Web of Science
2 Crossref

Gastrointestinal cancer

The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma: Seong Yong Park, Hong Kwan Kim, Yeong Jeong Jeon, Junghee Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jae Il Zo; Cancer Res Treat. 2023;55(4):1231-1239. Published online April 24, 2023; DOI: https://doi.org/10.4143/crt.2022.1417

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the efficacy of adjuvant chemotherapy after neoadjuvant chemoradiotherapy (CCRTx) followed by surgery in patients with esophageal squamous cell carcinoma (ESCC).
Materials and Methods
We retrospectively analyzed the data from 382 patients who received neoadjuvant CCRTx and esophagectomy for ESCC between 2003 and 2018.
Results
This study included 357 (93.4%) men, and the years median patient age was 63 (range, 40 to 84 years). Overall, 69 patients (18.1%) received adjuvant chemotherapy, whereas 313 patients (81.9%) did not. The median follow-up period was 28.07 months (interquartile range, 15.50 to 62.59). The 5-year overall survival (OS) and disease-free survival were 47.1% and 42.6%, respectively. Adjuvant chemotherapy did not improve OS in all patients, but subgroup analysis revealed that adjuvant chemotherapy improved the 5-year OS in patients with ypT+N+ (24.8% vs. 29.9%, p=0.048), whereas the survival benefit of adjuvant chemotherapy was not observed in patients with ypT0N0, ypT+N0, or ypT0N+. Multivariable analysis revealed that ypStage and adjuvant chemotherapy (hazard ratio, 0.601; p=0.046) were associated with OS in patients with ypT+N+. Freedom from distant metastasis was marginally different according to the adjuvant chemotherapy (48.3% vs. 41.3%, p=0.141).
Conclusion
Adjuvant chemotherapy after neoadjuvant therapy followed by surgery reduces the distant metastasis in ypT+N+ ESCC patients, thereby improving the OS. The consideration could be given to administration of adjuvant chemotherapy to ypT+N+ ESCC patients with tolerable conditions.

Citations

Citations to this article as recorded by

Impact of adjuvant therapy on survival in esophageal cancer patients after neoadjuvant therapy investigated by a population based cohort study
Jia-Lei Huang, Zi-Xin Lin, Ke-Yi Zeng, Zheng Lu, Xuan-Ping Lin, He-Rui Wang, Yong-Wei Xie, Jing-Rong Yang
Scientific Reports.2026;[Epub] CrossRef
Postoperative Adjuvant Therapy Benefits Non‐pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real‐World Study
Defeng Liu, Ao Liu, Longxiang Guo, Yi Li, Yuanlin Li, Yuxiang Chi, Haiqun Lin, Jinming Yu, Minghuan Li
Thoracic Cancer.2025;[Epub] CrossRef
Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation
Yoo Kyung Choi, Seok Hyun Son, Hong Seok Jang, In-Ho Kim, Sea-Won Lee, Soo-Yoon Sung, Satyajeet Rath
PLOS One.2025; 20(11): e0336794. CrossRef
Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study
Shu-Han Xie, Li-Tao Yang, Hai Zhang, Zi-Lu Tang, Zhi-Wei Lin, Yi Chen, Zhi-Nuan Hong, Rong-Yu Xu, Wan-Li Lin, Ming-Qiang Kang
Frontiers in Immunology.2024;[Epub] CrossRef
Clinical implications of C-reactive protein–albumin–lymphocyte (CALLY) index in patients with esophageal cancer
Ruiya Ma, Yoshinaga Okugawa, Tadanobu Shimura, Shinji Yamashita, Yuhki Sato, Chengzeng Yin, Ryo Uratani, Takahito Kitajima, Hiroki Imaoka, Mikio Kawamura, Yuhki Morimoto, Yoshiki Okita, Shigeyuki Yoshiyama, Masaki Ohi, Yuji Toiyama
Surgical Oncology.2024; 53: 102044. CrossRef
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study
Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen
Frontiers in Immunology.2024;[Epub] CrossRef

6,503 View
175 Download
9 Web of Science
6 Crossref

Lung and Thoracic cancer

Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non–Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry: Jeonghee Yun, Jong Ho Cho, Tae Hee Hong, Kyungmi Yang, Yong Chan Ahn, Hong Kwan Kim, Korean Association for Lung Cancer, Korea Central Cancer Registry; Cancer Res Treat. 2023;55(4):1171-1180. Published online April 17, 2023; DOI: https://doi.org/10.4143/crt.2022.1581

Abstract PDF Supplementary Material PubReader ePub

Purpose
Stereotactic body radiotherapy (SBRT) had been increasingly recognized as a favorable alternative to surgical resection in patients with high risk for surgery. This study compared survival outcomes between sublobar resection (SLR) and SBRT for clinical stage I non–small cell lung cancer (NSCLC).
Materials and Methods
Data were obtained from the Korean Association of Lung Cancer Registry, a sampled nationwide database. This study retrospectively reviewed 382 patients with clinical stage I NSCLC who underwent curative SLR or SBRT from 2014 to 2016.
Results
Of the patients, 43 and 339 underwent SBRT and SLR, respectively. Patients in the SBRT group were older and had worse pulmonary function. The 3-year overall survival (OS) rate was significantly better in the SLR group compared with the SBRT group (86.6% vs. 57%, log-rank p < 0.001). However, after adjusting for age, sex, tumor size, pulmonary function, histology, smoking history, and adjuvant therapy, treatment modality was not an independent prognostic factor for survival (hazard ratio, 0.99; 95% confidence interval, 0.43 to 2.77; p=0.974). We performed subgroup analysis in the following high-risk populations: patients who were older than 75 years; patients who were older than 70 years and had diffusing capacity of lung for carbon monoxide ≤ 80%. In each subgroup, there were no differences in OS and recurrence-free survival between patients who underwent SLR and those who received SBRT.
Conclusion
In our study, there were no significant differences in terms of survival or recurrence between SBRT and SLR in medically compromised stage I NSCLC patients. Our findings suggest that SBRT could be considered as a potential treatment option for selected patients.

Citations

Citations to this article as recorded by

Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients
Stijn Vanstraelen, Kay See Tan, Prasad S. Adusumilli, Manjit S. Bains, Matthew J. Bott, Robert J. Downey, Daniel R. Gomez, Katherine D. Gray, James Huang, James M. Isbell, Daniela Molena, Bernard J. Park, Andreas Rimner, Valerie W. Rusch, Narek Shaverdian
Annals of Surgery.2026; 283(5): 807. CrossRef
Sublobar resection, stereotactic body radiotherapy, and thermal ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis
Shahar Adar, Alexandra Ádám, Tamara Balogh, Mátyás Rédei, Karen Krisztina Fazekas, Mátyás Paczkó, Nina Galdzytska, Marie Anne Engh, András Bibok, Gábor Zoltán Duray, Péter Hegyi, Dénes Balázs Horváthy
Lung Cancer.2026; 217: 109467. CrossRef
The limits of pooled evidence in early-stage NSCLC: are we comparing treatments or patients?
Peter S.N. van Rossum, Famke L. Schneiders, Suresh Senan
Lung Cancer.2026; : 109555. CrossRef
Surgery Versus Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer (NSCLC): A Comprehensive Review of Survival and Local Control Outcomes
Abdulrahman Bin Sumaida, Nandan M Shanbhag, Nadeem Pervez, Khalifa AlKaabi, Khalid Balaraj
Cureus.2025;[Epub] CrossRef
Surgery for all patients with T1N0 non-small cell lung cancer?
Claudia Pouypoudat, Sébastien Thureau, Nicolas Giraud, Yaniss Belaroussi, Étienne Martin
Cancer/Radiothérapie.2025; 29(5-6): 104683. CrossRef

7,288 View
219 Download
5 Web of Science
5 Crossref

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015: Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung-Sik Hwang, Chang-Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry; Cancer Res Treat. 2023;55(1):103-111. Published online June 20, 2022; DOI: https://doi.org/10.4143/crt.2022.264

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
Materials and Methods
The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
Results
We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).
Conclusion
In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.

Citations

Citations to this article as recorded by

Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial
Niels Reinmuth, Sébastien Couraud, Luis Paz-Ares, Marina Chiara Garassino, Shobhit Baijal, Davey Daniel, Pilar Garrido, Terufumi Kato, Ivor Percent, Achim Rittmeyer, Hector Soto Parra, Sabeen Mekan, Mira Patel, Matthew Radford, Eric Zhang, Christopher G.
JTO Clinical and Research Reports.2026; 7(2): 100929. CrossRef
Exploring Sex and Clinical Factors Associated with Long-Term Survival After Implantable Cardioverter-Defibrillator Implantation: A 10-Year Cohort Study
Rebeca Lorca, María Salgado, Cristina Helguera, Alberto Alen, Francisco González-Urbistondo, Rosana González-Mesa, Paula Bouzón, Daniel García, Rodrigo Di Massa, Rut Álvarez-Velasco, José Manuel Rubín, Pablo Avanzas
Journal of Clinical Medicine.2026; 15(3): 1275. CrossRef
Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC
Subhamoy Chakraborty, Andrew Elliott, Utsav Sen, Charles Coleman, Vrinda Jethalia, Kedwin Ventura, Chih-Wei Fan, Ramja Sritharan, Avisek Banerjee, Yazhini Mahendravarman, Ari Vanderwalde, Balazs Halmos, Elisa de Stanchina, Hirokazu Taniguchi, Deniz Demirc
Nature Communications.2026;[Epub] CrossRef
Formulation of pullulan-assisted nanoparticles for improved dasatinib cytotoxicity in A549 lung carcinoma cells
Sunita S. Shinde, Aishwarya A. Lohar, Avinash H. Hosmani, Sameer J. Nadaf, Rohit R. Shah
Zeitschrift für Naturforschung C.2026;[Epub] CrossRef
Fragment-Based De Novo Discovery of Fourth-Generation EGFR-L858R/T790M/C797S-Tyrosine Kinase Inhibitors Targeting Catalytic Lys745 Residue to Overcome the Osimertinib Resistance
Prasanna Joshi, Manisha Modak, Harun Patel
Journal of Computational Biophysics and Chemistry.2026; 25(11): 2793. CrossRef
Design and application of a novel acridine-based fluorophore BAA12C as a theranostic agent
Dat Thanh Dinh, Chia-Ying Li, Ryan Joshua Liou, Xuan-Yu Chen, Min-Wei Wu, Cheng-Chung Chang
Sensors and Actuators Reports.2026; 11: 100460. CrossRef
Integrated analysis of therapeutic strategies and prognostic factors in advanced lung adenocarcinoma: Retrospective study with emphasis on gene assays, multimodality treatment approaches and predictive machine learning models
Shingchern You, Shiuan-Wen Chen, Irene Chen, Wei-Teing Chen
Oncology Letters.2026; 31(5): 1. CrossRef
FTO Acts as a Suppressor Gene to Inhibit the Translation of KDM5A mRNA by Demethylating m6A Modifications in Lung Adenocarcinoma
Wen Zhao, Chen Zhu, Ning Wang, Bin Wu, Xuelin Lu, Ye Xu, Zhijie Xu
International Journal of Genomics.2026;[Epub] CrossRef
Identification of Prognostic Risk Factors in Older Patients With Extensive‐Stage Small Cell Lung Cancer
Jiayin Liu, Xun Liu, Xiaolin Li, Ning Liu, Bo Wang, Li Feng, Zhisong Fan, Long Wang, Jing Han, Xue Zhang, Hui Jin, Dan Li, Yan Liu, Jing Zuo, Yudong Wang
Cancer Medicine.2026;[Epub] CrossRef
Trends and Outcomes of Lung Cancer Surgery in South Korea
Joon Beom Park, Su-Jin Cho, Myung-Il Hahm, Danbee Kang, Seong Yong Park
Cancer Research and Treatment.2026; 58(2): 443. CrossRef
Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling
Aging and Cancer.2026;[Epub] CrossRef
Real‐World Treatment and Outcomes in Resectable Early‐Stage Non‐Small Cell Cancer: THASSOS‐INTL Australia Cohort
Pei Ding, Kevin Jasas, Victoria Bray, Abhijit Pal, Rebecca Moor
AGING MEDICINE.2026; 9(2): 137. CrossRef
Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors
Lai Wei, Mengxing Tian, Qian Han, Wen Wang, Xin Jin, Xintian Xu
Clinical Nutrition ESPEN.2026; 73: 103288. CrossRef
AptoDetect™-Lung Assay as a Blood-Based Predictor of Advanced-Stage Lung Cancer in Patients with Lung-RADS 3–4 Pulmonary Nodules: A Multicenter Prospective Cohort Study
Bora Lee, Chi Young Kim, Jung Seop Eom, Wonjun Ji, Min Jee Kim, Sung Hoon Yoon, June Hong Ahn, Jun Hyeok Lim, Chaeuk Chung, Dong Won Park, Seung Hyeun Lee, Chang Dong Yeo
Biomedicines.2026; 14(5): 1013. CrossRef
Functional Precision Oncology Approach Using Nanoliter Droplet Array for Drug Sensitivity Testing in Lung Cancer
Maryam Salarian, Vicky L. Schiling, Thomas Muley, Michael Allgäuer, Florian Eichhorn, Michael Meister, Marc A. Schneider, Anna A. Popova
Advanced Healthcare Materials.2026;[Epub] CrossRef
Differences in long-term survival according to the underlying cardiomyopathy indication for implantable cardioverter-defibrillator implantation
Rebeca Lorca, Paula Bouzón, Fernando López, María Salgado, Rosana González-Mesa, Francisco González-Urbistondo, Cristina Helguera, Alberto Alen, Alvaro Lorente, Rut Alvarez-Velasco, José Manuel Rubín, Pablo Avanzas
International Journal of Cardiology.2026; 458: 134561. CrossRef
SLC2A1-Dependent Ketone Metabolism Regulates Tumor Progression and Immunotherapy Efficacy in Lung Adenocarcinoma
Xing Feng, Li Gao, Yonggang Xue, Yanbing Zhang, Hongyou Cao, Tianchang Wange
Critical Reviews in Immunology.2026; 46(2): 59. CrossRef
AI-Driven Preoperative Chest Radiograph Analysis for Prognostic Stratification in Surgically Resected Pathological Stage 1 Non-Small Cell Lung Cancer
Hyun Joo Shin, Eun Hye Lee, Se Hyun Kwak, Na Young Kim, Eun-Kyung Kim, Young Joo Suh
Journal of Imaging Informatics in Medicine.2026;[Epub] CrossRef
Novel strategy of pemetrexed combined with localized therapy: breakthrough impact of long-term maintenance regimen on patient survival—a case report
Dan Liu, Xiaobiao Ma, Chunlei Ge, Qian Huang, Yiqing Duan, Li Li
Journal of Medical Case Reports.2026;[Epub] CrossRef
Molecular‐Based Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage Lung Cancer: A Systematic Review and Meta‐Analysis
Aaron Ling, Evangeline Samuel, Rahini Mahendran, John Zalcberg, Rob G. Stirling
Thoracic Cancer.2026;[Epub] CrossRef
Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis
Junfang Zhang, Xuan Tang, Wenbo Zhang, Ying Xu, Heng Zhang, Yu Fan
International Journal of Obesity.2025; 49(1): 13. CrossRef
Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors
Fabrice N. Njotu, Jessica Pougoue Ketchemen, Hanan Babeker, Nikita Henning, Anjong F. Tikum, Emmanuel Nwangele, Alissar Monzer, Nava Hassani, Brian D. Gray, Koon Y. Pak, Emina E. Torlakovic, Maruti Uppalapati, Humphrey Fonge
European Journal of Nuclear Medicine and Molecular Imaging.2025; 52(4): 1305. CrossRef
Interactions and communications in lung tumour microenvironment: chemo/radiotherapy resistance mechanisms and therapeutic targets
Yuan Feng, Ying Jiang, Lin Yang, Danni Lu, Ning Li, Qun Zhang, Haiyan Yang, Huiyuan Qin, Jiaxin Zhang, Xinyun Gou, Feng Jiang
Journal of Drug Targeting.2025; 33(6): 817. CrossRef
The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
Yanchao Luan, Chao Liang, Qingsong Han, Xueqin Zhou, Na Yang, li Zhao
BMC Cancer.2025;[Epub] CrossRef
Secretome and Proteome of Extracellular Vesicles Provide Protein Markers of Lung and Colorectal Cancer
Natalia Soloveva, Svetlana Novikova, Tatiana Farafonova, Olga Tikhonova, Victor Zgoda
International Journal of Molecular Sciences.2025; 26(3): 1016. CrossRef
Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
Lu Zheng, Yanzhu Bian, Yujing Hu, Congna Tian, Xinchao Zhang, Shuheng Li, Xin Yang, Yanan Qin
Frontiers in Medicine.2025;[Epub] CrossRef
Artificial intelligence-assisted point-of-care devices for lung cancer
Xin Jie Keith Ng, Anis Salwa Mohd Khairuddin, Hai Chuan Liu, Thian Chee Loh, Jiunn Liang Tan, Sook Mei Khor, Bey Fen Leo
Clinica Chimica Acta.2025; 570: 120191. CrossRef
Genetic Navigation: A Narrative Review of XRCC1 Polymorphism Impact on Platinum-Based Chemotherapy Outcomes in NSCLC Patients
Lanny Permatasari, Nadiya Afifah, Maryam Ishmatullah, Ruri Intania, Eli Halimah, Melisa Barliana
Cancer Management and Research.2025; Volume 17: 383. CrossRef
Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study
Qi-An Wang, I-Lin Tsai, Chien-Yu Lin, Po-Lan Su, Chien-Chung Lin, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Cheng-Ta Yang, Chiao-En Wu
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Ex-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis
Jenny Zipprick, Enes Demir, Hanna Krynska, Sıla Köprülüoğlu, Katharina Strauß, Marcus Skribek, Rita Hutyra-Gram Ötvös, Annica K. B. Gad, Katalin Dobra
Cancers.2025; 17(6): 986. CrossRef
Defining long-term survivors in metastatic lung cancer: insights from a Delphi study in Spain
Enric Carcereny, Manuel Domine, Ana Laura Ortega Granados
Frontiers in Oncology.2025;[Epub] CrossRef
Genomics and the early diagnosis of lung cancer
Francesco Pepe, Tancredi Didier Bazan Russo, Valerio Gristina, Andrea Gottardo, Giulia Busuito, Giuliana Iannì, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Viviana Bazan, Antonio Russo, Giancarl
Personalized Medicine.2025; 22(3): 161. CrossRef
Single-cell transcriptomics and machine learning unveil ferroptosis features in tumor-associated macrophages: Prognostic model and therapeutic strategies for lung adenocarcinoma
Ting Ji, Juanli Jiang, Xin Wang, Kai Yang, Shaojin Wang, Bin Pan
Frontiers in Pharmacology.2025;[Epub] CrossRef
Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression
Chen Chen, Ji Chen, Yanling Zhang, Qijun Zhang, Haixia Shi
Frontiers in Oncology.2025;[Epub] CrossRef
A Systematic Review and Meta-Analysis of the Efficacy and Safety of Lazertinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Louis Fabio Jonathan Jusni, Eric Ricardo Yonatan, Nicolas Daniel Widjanarko, Rio Gusta Notario Besri
Hematology/Oncology and Stem Cell Therapy.2025; 18(2): 48. CrossRef
The predictive value of ferroptosis marker SLC7A11 in the prognosis of advanced non-small cell lung cancer patients
Shiqiang Wang, Xinlai Jin, Xuefei Yang, Zhidi Zhang
Clinical Biochemistry.2025; 138: 110961. CrossRef
p53 aberrant expression is pervasive in pleomorphic carcinomas of the lung and a sensitive diagnostic adjunct for biopsy specimens
Joshua Jing Xi Li, Chit Chow, Joanna Ka Man Ng, Ka Pang Chan, Molly Siu Ching Li, Ka-Fai To
Diagnostic Pathology.2025;[Epub] CrossRef
Diagnostic performance of artificial intelligence models for pulmonary nodule classification: a multi-model evaluation
Sarah K. Herber, Lukas Müller, Daniel Pinto dos Santos, Tobias Jorg, Fabio Souschek, Tobias Bäuerle, Sebastian Foersch, Christian Galata, Peter Mildenberger, Moritz C. Halfmann
European Radiology.2025; 36(1): 537. CrossRef
Small-Cell Lung Cancer Updates
Yunan Nie, Anne C. Chiang
Seminars in Respiratory and Critical Care Medicine.2025; 46(05): 467. CrossRef
A shape complementarity strategy based on NCA029 enables potent HsClpP agonists for the treatment of small cell lung carcinoma
Linjie Li, Baozhu Luo, Xudong Wang, Zhongyu Jian, Hong Liu, Bo Ren, Wenliang Qiao, Youfu Luo, Tao Yang
European Journal of Medicinal Chemistry.2025; 299: 118008. CrossRef
CLDN4 regulates cell proliferation in small cell lung cancer cells via SAA1 inhibition
Korehito Kashiwagi, Hanako Sato-Yazawa, Jun Ishii, Masami Iwamoto, Kakeru Kohno, Tadasuke Miyazawa, Tamotsu Kamimura, Shunsuke Miyata, Ruri Sugiyama, Hideki Chiba, Takuya Yazawa
Biochemical and Biophysical Research Communications.2025; 785: 152710. CrossRef
Autophagy inhibition enhances sensitivity of alpelisib in PI3K–mutated non-small cell lung cancer
Jinyoung Kim, Chandani Shrestha, Tae Woo Kim, Sang-Bin Lee, Gwangbin Lee, Dasom Jung, Min Hwang, Shinwon Kang, Hyung Soon Park, Hyunho Kim, Ho Jung An, Dongwoo Chae, Byoung Yong Shim, Jiyoon Kim
Biomedicine & Pharmacotherapy.2025; 192: 118620. CrossRef
Lung Cancer Management: A Comprehensive Review with Special Focus on Natural Remedies and Bioactive Compounds
Raj Shekhar, P. Muralidharan, Namrata Hallur, S. B. Puranik, Phatru Patel
Journal of Natural Remedies.2025; : 1989. CrossRef
Ferroptosis and non-coding RNAs in lung cancer: exploring molecular mechanisms and diagnostic/therapeutic implications
Hedong Xue, Melika Malek, Liangyu Li
Cancer Cell International.2025;[Epub] CrossRef
Association of Pre‐ and Postdiagnosis Physical Activity, Promotion and Maintenance With Lung Cancer Survival: A Nationwide Cohort Study
Yeon Wook Kim, Kyeong Im Kwak, A‐Reum Choi, Eung Joo Park, Brian J. Lee, Yeon Joo Lee, Choon‐Taek Lee
Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future
Gian Marco Leone, Grazia Scuderi, Paolo Fagone, Katia Mangano
International Journal of Molecular Sciences.2025; 26(22): 11055. CrossRef
Radiogenomic insights from a Portuguese lung cancer cohort: Foundations for predictive modeling
Inês Neves, Cláudia Freitas, Carolina Lemos, Hélder P. Oliveira, Venceslau Hespanhol, Manuela França, Tania Pereira
Measurement and Evaluations in Cancer Care.2025; 3: 100025. CrossRef
Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases
Yu-An Zheng, Ke-Cheng Chen, Pei-Ming Huang, Mong-Wei Lin, Shuenn-Wen Kuo, Jang-Ming Lee
Oncology.2025; 104(7): 733. CrossRef
Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study
Khanh Toan Nguyen, Thi Huong Pham, Van Lam Ngo, Thi Thuy My Nguyen, Thi Dao Nguyen, Van Thanh Le, Van Nhat Nguyen, Thi Thanh Thuy Nguyen, Khanh Ha Nguyen, Thi Nhung Ngo, Thi Hai Yen Le, Thi Phuong Thao Nguyen, Thi Ha Phuong Nguyen, Thi Hong Anh Vo, Thi Th
Journal of Immunotherapy and Precision Oncology.2025; 8(4): 254. CrossRef
Spatial Dynamics of Tumor Cell Plasticity in Lung Adenocarcinoma Revealed by Region‐Specific Single Cell Transcriptomics
Anna A. Khozyainova, Maxim E. Menyailo, Vera G. Subrakova, Dmitry M. Loos, Pavel S. Iamshchikov, Anton A. Fedorov, Maria S. Tretyakova, Ustinia A. Bokova, Evgeny O. Rodionov, Sergey V. Miller, Evgeny B. Topolnitsky, Denis V. Piankov, Sergei A. Korostelev,
Genes, Chromosomes and Cancer.2025;[Epub] CrossRef
Inflammatory cytokine-associated cisplatin resistance in non-small cell lung cancer and re-sensitization through interleukin-6 receptor blockade
Gizem Calibasi-Kocal
World Journal of Clinical Oncology.2025;[Epub] CrossRef
Anti-cancer Effects of Sargassum micracanthum Extract on Non-small Cell Lung Cancer Cells
Hyun-Ji Park, Seon-Eun Park, Gyoo-Yong Chi, Yung-Hyun Choi, Shin-Hyung Park
Journal of Physiology & Pathology in Korean Medicine.2025; 39(5): 120. CrossRef
Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim
Cancer Research and Treatment.2024; 56(1): 104. CrossRef
The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round
Alberto Antonicelli, Piergiorgio Muriana, Giovanni Favaro, Giuseppe Mangiameli, Ezio Lanza, Manuel Profili, Fabrizio Bianchi, Emanuela Fina, Giuseppe Ferrante, Simone Ghislandi, Daniela Pistillo, Giovanna Finocchiaro, Gianluigi Condorelli, Rosalba Lembo,
Cancers.2024; 16(2): 417. CrossRef
Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
Hyeon Hwa Kim, Jae Cheol Lee, In-Jae Oh, Eun Young Kim, Seong Hoon Yoon, Shin Yup Lee, Min Ki Lee, Jeong Eun Lee, Chan Kwon Park, Kye Young Lee, Sung Yong Lee, Seung Joon Kim, Jun Hyeok Lim, Chang-min Choi
Cancers.2024; 16(3): 528. CrossRef
Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation
Theofanis Vavilis, Maria Louiza Petre, Giannis Vatsellas, Alexandra Ainatzoglou, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Ioannis N. Vamvakaris, Ioannis Gkiozos, Konstantinos N. Syrigos, Athanasios K. Anagnostopoulos
Cancers.2024; 16(6): 1236. CrossRef
Survival analysis and gender differences in hypertrophic cardiomyopathy proband patients referred for genetic testing
Rebeca Lorca, María Salgado, Rut Álvarez-Velasco, Julián R. Reguro, Vanesa Alonso, Juan Gómez, Eliecer Coto, Elías Cuesta-Llavona, Eva Lopez-Negrete, Isaac Pascual, Pablo Avanzas, Maite Tome
International Journal of Cardiology.2024; 408: 132117. CrossRef
18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer
Chae Hong Lim, Sang-Won Um, Hong Kwan Kim, Yong Soo Choi, Hong Ryul Pyo, Myung-Ju Ahn, Joon Young Choi
Cancers.2024; 16(14): 2525. CrossRef
Study Progress of Circulating miRNA for Predicting Metastasis in Non-Small Cell Lung Cancer
靖靖丛
Advances in Clinical Medicine.2024; 14(07): 65. CrossRef
Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression
Jolanta Smok-Kalwat, Paulina Mertowska, Sebastian Mertowski, Stanisław Góźdź, Ewelina Grywalska
Journal of Clinical Medicine.2024; 13(15): 4531. CrossRef
Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer
Cameron J. Oswalt, Morgan M. Nakatani, Jesse Troy, Steven Wolf, Susan C. Locke, Thomas W. LeBlanc
Journal of Pain and Symptom Management.2024; 68(4): e325. CrossRef
Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen–Autoantibody Immune Complexes against CYFRA 21-1 and p53
Heyjin Kim, Jin Kyung Lee, Hye-Ryoun Kim, Young Jun Hong
Cancers.2024; 16(15): 2661. CrossRef
Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile
Chinbayar Batochir, In Ae Kim, Eun Ji Jo, Eun-Bi Kim, Hee Joung Kim, Jae Young Hur, Do Won Kim, Hee Kyung Park, Kye Young Lee
Cancers.2024; 16(15): 2765. CrossRef
The clinical significance of endoplasmic reticulum stress related genes in non-small cell lung cancer and analysis of single nucleotide polymorphism for CAV1
Shuang Li, Junting Chen, Baosen Zhou
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
A Highly Sensitive Toluene Gas Sensor Based on Pd/PdO Decorated SnO2 Prepared by Electrospinning
Chengyi Gong, Meng Chen, Fei Song, Peisi Yin, Xin Zhao, Xiaoyu You, Huaian Fu, Shanshan Yu, Xingyu Liu, Kai Zhang, Yongqi Yang, Zhipeng Tang, Xiangmin Du, Jiacong Xu, Qiang Jing, Bo Liu
ACS Applied Electronic Materials.2024;[Epub] CrossRef
miR-137: a potential therapeutic target for lung cancer
Shuanshuan Liu, Yanyun Ruan, Xu Chen, Bao He, Qi Chen
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef
Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer
Tianxing Hu, Jiali Huang, Rui Chen, Hui Zhang, Mai Liu, Renbing Wang, Wenyi Zhou, Dechun Huang, Mingkang Cao, Depeng Li, Zhiyu Li, Hongxi Wu, Jinlei Bian
European Journal of Medicinal Chemistry.2024; 280: 116952. CrossRef
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Autumn Gaither-Davis, Yufei Huang, Timothy F. Burns, Laura P. Stabile, Shou-Jiang Gao
Cell & Bioscience.2024;[Epub] CrossRef
RETRACTED: Methylation modification is a poor prognostic factor in non-small cell lung Cancer and regulates the tumor microenvironment: mRNA molecular structure and function
Kai Yang, YuPing Yang, Lin Yu, Fan Yang, YuXin Xiang, Jun Zeng, Na Huang
International Journal of Biological Macromolecules.2024; 282: 137214. CrossRef
Impact of Postoperative Prolonged Air Leakage on Long-Term Pulmonary Function after Lobectomy for Lung Cancer
June Yeop Lee, Joonseok Lee, Varissara Javakijkarnjanakul, Beatrice Chia-Sui Shih, Woohyun Jung, Jae Hyun Jeon, Kwhanmien Kim, Sanghoon Jheon, Sukki Cho
Journal of Chest Surgery.2024; 57(6): 511. CrossRef
M1 macrophage-related prognostic model by combining bulk and single-cell transcriptomic data in NSCLC
Liu Zhe, Liu Fang, Petinrin Olutomilayo Olayemi, Toseef Muhammad, Chen Nanjun, Zhu Zhongxu, Wong Ka-Chun
Exploration of Medicine.2024;[Epub] CrossRef
Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring
Michele Tomanelli, Federica Guffanti, Giulia Vargiu, Edoardo Micotti, Mara Rigamonti, Francesca Tumiatti, Elisa Caiola, Mirko Marabese, Massimo Broggini
Frontiers in Oncology.2024;[Epub] CrossRef
Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection
Silvia D’Ambrosi, Stavros Giannoukakos, Mafalda Antunes-Ferreira, Carlos Pedraz-Valdunciel, Jillian W. P. Bracht, Nicolas Potie, Ana Gimenez-Capitan, Michael Hackenberg, Alberto Fernandez Hilario, Miguel A. Molina-Vila, Rafael Rosell, Thomas Würdinger, Da
International Journal of Molecular Sciences.2023; 24(5): 4881. CrossRef
Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years
Jee Seon Kim, Eun Ji Kim, Jong Geol Jang, Kyung Soo Hong, June Hong Ahn
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7275. CrossRef
Prior treated tuberculosis and mortality risk in lung cancer
Kuang-Ming Liao, Chung-Shu Lee, Yu-Cih Wu, Chin-Chung Shu, Chung-Han Ho
Frontiers in Medicine.2023;[Epub] CrossRef
All-round counterattack to conquer lung cancer
Seung Hun Jang
Journal of the Korean Medical Association.2023; 66(3): 154. CrossRef
Metabolic profiles of lung adenocarcinoma via peripheral blood and diagnostic model construction
Kyung Soo Kim, Seok Whan Moon, Mi Hyung Moon, Kwan Yong Hyun, Seung Joon Kim, Young Koon Kim, Kwang Youl Kim, Dong Wook Jekarl, Eun-Jee Oh, Yonggoo Kim
Scientific Reports.2023;[Epub] CrossRef
STEMI in women. Life expectancy recovery after primary percutaneous coronary intervention
Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
Revista Española de Cardiología (English Edition).2023; 76(12): 1003. CrossRef
A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer Patients
Bogdan Cosmin Tanase, Alin Ionut Burlacu, Claudiu Eduard Nistor, Teodor Horvat, Cristian Oancea, Monica Marc, Emanuela Tudorache, Tudor Mateescu, Diana Manolescu
Healthcare.2023; 11(12): 1745. CrossRef
IAMCEST en mujeres. Recuperación de la expectativa de vida tras la intervención coronaria percutánea
Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
Revista Española de Cardiología.2023; 76(12): 1003. CrossRef
Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
JMIR Medical Informatics.2023; 11: e47859. CrossRef
Exosomes in lung cancer metastasis, diagnosis, and immunologically relevant advances
Jianhua Zhao, Xiwen Li, Lele Liu, Zhen Zhu, Chunyan He
Frontiers in Immunology.2023;[Epub] CrossRef

22,584 View
623 Download
97 Web of Science
82 Crossref

The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study: Seong Yong Park, Samina Park, Geun Dong Lee, Hong Kwan Kim, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Tae Hee Hong, Yong Soo Choi, Jhingook Kim, Jong Ho Cho, Young Mog Shim, Jae Ill Zo, Kwon Joong Na, In Kyu Park, Chang Hyun Kang, Young-Tae Kim, Byung Jo Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik; Cancer Res Treat. 2023;55(1):94-102. Published online June 9, 2022; DOI: https://doi.org/10.4143/crt.2022.290

Abstract PDF Supplementary Material PubReader ePub

Purpose
This multi-center, retrospective study was conducted to evaluate the long-term survival in patients who underwent surgical resection for small cell lung cancer (SCLC) and to identify the benefit of adjuvant therapy following surgery.
Materials and Methods
The data of 213 patients who underwent surgical resection for SCLC at four institutions were retrospectively reviewed. Patients who received neoadjuvant therapy or an incomplete resection were excluded.
Results
The mean patient age was 65.29±8.93 years, and 184 patients (86.4%) were male. Lobectomies and pneumonectomies were performed in 173 patients (81.2%), and 198 (93%) underwent systematic mediastinal lymph node dissections. Overall, 170 patients (79.8%) underwent adjuvant chemotherapy, 42 (19.7%) underwent radiotherapy to the mediastinum, and 23 (10.8%) underwent prophylactic cranial irradiation. The median follow-up period was 31.08 months (interquartile range, 13.79 to 64.52 months). The 5-year overall survival (OS) and disease-free survival were 53.4% and 46.9%, respectively. The 5-year OS significantly improved after adjuvant chemotherapy in all patients (57.4% vs. 40.3%, p=0.007), and the survival benefit of adjuvant chemotherapy was significant in patients with negative node pathology (70.8% vs. 39.7%, p=0.004). Adjuvant radiotherapy did not affect the 5-year OS (54.6% vs. 48.5%, p=0.458). Age (hazard ratio [HR], 1.032; p=0.017), node metastasis (HR, 2.190; p < 0.001), and adjuvant chemotherapy (HR, 0.558; p=0.019) were associated with OS.
Conclusion
Adjuvant chemotherapy after surgical resection in patients with SCLC improved the OS, though adjuvant radiotherapy to the mediastinum did not improve the survival or decrease the locoregional recurrence rate.

Citations

Citations to this article as recorded by

Cold Atmospheric Plasma‐Activated Decellularized Extracellular Matrix Gel as a Tumor‐Infiltrating Immunoactivation Platform for Post‐Surgical Cancer Immunotherapy
Tianxu Fang, Mo Chen, Yueyang Deng, Tianqin Ning, Tianwen Luo, Guojun Chen
Advanced Materials.2026;[Epub] CrossRef
Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis
Chuanhao Zhang, Genghao Zhao, Huajian Wu, Jianing Jiang, Wenyue Duan, Zhijun Fan, Zhe Wang, Ruoyu Wang
Radiotherapy and Oncology.2024; 193: 110123. CrossRef
A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection
Sevcan Atay
Cancers.2023; 15(21): 5219. CrossRef

10,266 View
161 Download
5 Web of Science
3 Crossref

Psychometric Validation of the Korean Version of the Cancer Survivors’ Unmet Needs (CaSUN) Scale among Korean Non–Small Cell Lung Cancer Survivors: Danbee Kang, Genehee Lee, Sooyeon Kim, Heesu Nam, Sunga Kong, Sungkeun Shim, Jae Kyung Lee, Wonyoung Jung, Sumin Shin, Hong Kwan Kim, Jae Ill Zo, Young Mog Shim, Dong Wook Shin, Juhee Cho; Cancer Res Treat. 2023;55(1):61-72. Published online February 23, 2022; DOI: https://doi.org/10.4143/crt.2021.1583

Abstract PDF PubReader ePub

Purpose
The purpose of the study was to validate the Korean version of Cancer Survivors’ Unmet Needs (CaSUN) scale among non–small cell lung cancer survivors.
Materials and Methods
Participants were recruited from outpatient clinics at the Samsung Medical Center in Seoul, South Korea, from January to October 2020. Participants completed a survey questionnaire that included the CaSUN. Exploratory and confirmatory factor analysis and Pearson’s correlations were used to evaluate the reliability and validity of the Korean version of the CaSUN (CaSUN-K). We also tested known-group validity using an independent t test or ANOVA.
Results
In total, 949 provided informed consent and all of which completed the questionnaire. Among the 949 patients, 529 (55.7%) were male; the mean age and median time since the end of active treatment (standard deviation) was 63.4±8.8 years and the median was 18 months. Although the factor loadings were different from those for the original scale, the Cronbach’s alpha coefficients of the six domains in the CaSUN-K ranged from 0.68 to 0.95, indicating satisfactory internal consistency. In the CFA, the goodness-of-fit indices for the CaSUN-K were high. Moderate correlations demonstrated the convergent validity of CaSUN-K with the relevant questionnaire. More than 60% of the participants reported information-related unmet needs, and the CaSUN-K discriminated between the needs reported by the different subgroups that we analyzed.
Conclusion
The CaSUN-K is a reliable and valid measure for assessing the unmet needs in a cancer population, thus this tool help population to receive timely, targeted, and relevant care.

Citations

Citations to this article as recorded by

Protocol Development for the Korean Survey for Cancer Survivorship and Preliminary Analysis of Employment Change’s Impact on Quality of Life and Psychological Health
Janine Marie Balbedina, Yeol Kim, Hye Joo Jang, Ha Yeong You, Jae Hyun Park, Hyun Woo Lee, Ji Soo Park, Yu Ri Choe, Kyu Won Jung
Cancers.2026; 18(2): 219. CrossRef
Unmet needs among long-term breast cancer survivors
Rina A. Yarosh, Hazel B. Nichols, Rachel Hirschey, Erin E. Kent, Deborah K. Mayer, Melissa A. Troester, Eboneé N. Butler
Cancer Causes & Control.2025; 36(8): 803. CrossRef
Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial
Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin
JMIR Research Protocols.2024; 13: e54707. CrossRef
Validity and Reliability of a Simplified Chinese Version of Cancer Survivors' Unmet Needs Scale (CaSUN)
Xiaojingyuan Xu, Xiaoyun Liang, Shiquan Yin
Psycho-Oncology.2024;[Epub] CrossRef
Unmet Supportive Care Needs after Non-Small Cell Lung Cancer Resection at a Tertiary Hospital in Seoul, South Korea
Junhee Park, Wonyoung Jung, Genehee Lee, Danbee Kang, Young Mog Shim, Hong Kwan Kim, Ansuk Jeong, Juhee Cho, Dong Wook Shin
Healthcare.2023; 11(14): 2012. CrossRef
Kanserden Kurtulanların Karşılanmayan İhtiyaçları Ölçeğinin Türkçeye Uyarlanması: Geçerlik ve Güvenirlik Çalışması
Gülyeter Erdoğan Yüce, Gamze Muz, Ayser Döner
Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi.2023; 10(3): 264. CrossRef
Psychometric properties of the Slovenian version of the Cancer Survivors’ Unmet Needs (CaSUN-SL) measure in post-treatment cancer survivors
Špela Miroševič, Polona Selič-Zupančič, Judith Prins, Vesna Homar, Zalika Klemenc-Ketiš
BMC Psychology.2022;[Epub] CrossRef

9,347 View
205 Download
5 Web of Science
7 Crossref

Lung Cancer

Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival: Dong Wook Shin, Jong Ho Cho, Jung Eun Yoo, Juhee Cho, Dong Woog Yoon, Genehee Lee, Sumin Shin, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim; Cancer Res Treat. 2021;53(4):1057-1071. Published online March 9, 2021; DOI: https://doi.org/10.4143/crt.2020.1308

Abstract PDF PubReader ePub

Purpose
Survival probability changes over time in cancer survivors. This study examined conditional survival in patients undergoing curative resection for non-small cell lung cancer (NSCLC).
Materials and Methods
Five-year conditional recurrence-free survival (CRFS), conditional overall survival (COS), and conditional relative survival (CRS) up to 10 years after surgery were calculated in patients who underwent NSCLC resection from 1994 to 2016. These rates were stratified according to age, sex, year of diagnosis, pathological stage, tumor histology, smoking status, comorbidity, and lung function.
Results
Five-year CRFS increased from 65.6% at baseline to 90.9% at 10 years after surgery. Early differences in 5-year CRFS according to stratified patient characteristics disappeared, except for age: older patients exhibited persistently lower 5-year CRFS. Five-year COS increased from 72.7% to 78.3% at 8 years and then decreased to 75.4% at 10 years. Five-year CRS increased from 79.0% at baseline to 86.8% at 10 years. Older age and higher pathologic stage were associated with lower 5-year COS and CRS up to 10 years after surgery. Female patients, those with adenocarcinoma histology, non-smokers, patient without comorbidities and had good lung function showed higher COS and CRS.
Conclusion
CRFS improved over time, but significant risk remained after 5 years. CRS slightly improved over time but did not reach 90%, suggesting significant excess mortality compared to the general population. Age and stage remained significant predictors of conditional survival several years after surgery. Our conditional survival estimates should help clinicians and patients make informed treatment and personal life decisions based on survivorship status.

Citations

Citations to this article as recorded by

A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States
Amy L. Cummings, Jesse Sussell, Katherine L. Rosettie, Fadoua El Moustaid, Sarika Ogale, Celina Ngiam, Nick Jovanoski, Melina Arnold, Jay M. Lee
American Journal of Clinical Oncology.2026; 49(5): 205. CrossRef
Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer
Giovanni Leuzzi, Federica Sabia, Matteo Calderoni, Clarissa Uslenghi, Ugo Pastorino, Alfonso Marchianò, Michele Ferrari, Alessandro Pardolesi, Daniele Lorenzini, Giuseppe Lo Russo, Claudia Proto, Arsela Prelaj, Piergiorgio Solli
Cancers.2026; 18(3): 367. CrossRef
Conditional survival after curative resection for extrahepatic cholangiocarcinoma: a comprehensive analysis of overall, recurrence-free, and relative survival
Hea Lim Choi, Danbee Kang, In Woon Han, Hong Kwan Kim, Hyeong Seok Kim, Sang Hyun Shin, Jin Seok Heo, Dong Wook Shin, Hongbeom Kim
HPB.2026; 28(6): 782. CrossRef
CT-Based Radiomics Predicts the Functional State of Tumor-Infiltrating CD8+ T Cells and Prognosis in NSCLC
Baojun Sang, Xiaoyu Zang, Jingkai Yu, Liying Yang, Guanqun Yang, Xiaodan Geng, Mei Zheng, Haoran Qi, Qingtao Qiu, Fanghan Cao, Ligang Xing, Xiaorong Sun
Academic Radiology.2026; 33(5): 2293. CrossRef
Real-World Mapping of Multiple Primary Carcinoma Combinations and Survival Outcomes in Shanghai, China: Retrospective Registry-Based Study
Jianwei Shi, Yichen Chen, Chen Chen, Xiaopan Li, Hua Jin
JMIR Public Health and Surveillance.2026; 12: e82355. CrossRef
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study
Giannis Mountzios, Sofia Lampaki, Helena Linardou, Vassilis Georgoulias, Dimitrios Mavroudis, Stavros Anevlavis, Andriani Charpidou, Maria Lykka, Dionysis Spyratos, Evangelos G Sarris, Alvertos Somarakis, Christina Papista, Alexandros Glentis, Aristeidis
Future Oncology.2025; 21(4): 447. CrossRef
COL3A1‐positive endothelial cells influence LUAD prognosis and regulate LUAD carcinogenesis by NCL–PI3K–AKT axis
Moyan Zhang, Yicheng Liang, Peng Song
The Journal of Gene Medicine.2024;[Epub] CrossRef
Adjustment to “new normal” after cancer among non–small cell lung cancer survivors: A qualitative study
Genehee Lee, Soo Yeon Kim, Alice Ahn, Sunga Kong, Heesu Nam, Danbee Kang, Hong Kwan Kim, Young Mog Shim, Ansuk Jeong, Dong Wook Shin, Juhee Cho
Palliative and Supportive Care.2024; 22(3): 487. CrossRef
Spatial features of specific CD103+CD8+ tissue-resident memory T cell subsets define the prognosis in patients with non-small cell lung cancer
Guanqun Yang, Siqi Cai, Mengyu Hu, Chaozhuo Li, Liying Yang, Wei Zhang, Jujie Sun, Fenghao Sun, Ligang Xing, Xiaorong Sun
Journal of Translational Medicine.2024;[Epub] CrossRef
Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial
Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin
JMIR Research Protocols.2024; 13: e54707. CrossRef
Conditional Survival of Patients with Limited-Stage Small Cell Lung Cancer After Surgery: A National Real-World Cohort Study
Jun-Peng Lin, Xiao-Feng Chen, Peiyuan Wang, Hao He, Wei-Jie Chen, Feng-Nian Zhuang, Hang Zhou, Yu-Jie Chen, Wen-Wei Wei, Shuo-Yan Liu, Feng Wang
Annals of Surgical Oncology.2024; 31(7): 4250. CrossRef
Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
Qiran Wei, Yifang Liang, Jiahui Mao, Xin Guan
Cancer Medicine.2024;[Epub] CrossRef
Bioinformatics-based modeling of lung squamous cell carcinoma prognosis and prediction of immunotherapy response
Qiqing Zhang, Haidong He, Yi Wei, Guoping Li, Lu Shou
Discover Oncology.2024;[Epub] CrossRef
Dynamic evaluation of postoperative survival in intrahepatic cholangiocarcinoma patients who did not undergo lymphadenectomy: a multicenter study
Tingfeng Huang, Jie Kong, Hongzhi Liu, Zhipeng Lin, Qizhu Lin, Jianying Lou, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Yamin Zheng, Jingdong Li, Shi Cheng, Weiping Zhou, Yongyi Zeng
Scandinavian Journal of Gastroenterology.2023; 58(2): 178. CrossRef
A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages
Ying Bai, Xin Zhang, Jiawei Zhou, Jianqiang Guo, Yafeng Liu, Chao Liang, Wenyang Wang, Yingru Xing, Jing Wu, Dong Hu
Chemico-Biological Interactions.2023; 382: 110543. CrossRef
Survival and Quality-of-life Outcomes in Early-Stage NSCLC Patients: a Literature Review of Real-World Evidence
Nick Jovanoski, Kathleen Bowes, Audrey Brown, Rossella Belleli, Danilo Di Maio, Shkun Chadda, Seye Abogunrin
Lung Cancer Management.2023;[Epub] CrossRef
Conditional survival analysis of patients with resected non–small cell lung cancer
Talib Chaudhry, Vaishnavi Krishnan, Andrew E. Donaldson, Zachary M. Palmisano, Sanjib Basu, Nicole M. Geissen, Justin M. Karush, Gillian C. Alex, Jeffrey A. Borgia, Michael J. Liptay, Christopher W. Seder
JTCVS Open.2023; 16: 948. CrossRef
Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy
Chae Hong Lim, Soo Bin Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Yong Chan Ahn, Myung-ju Ahn, Joon Young Choi
Cancers.2022; 14(3): 632. CrossRef
Primary care‐based lung and breast cancer control in China: A commentary on lessons learnt from Korea
Heng Piao, Harry H. X. Wang, Hyejin Lee, Mingyang Yu, Belong Cho
European Journal of Cancer Care.2022;[Epub] CrossRef
Conditional survival nomogram predicting real-time prognosis of locally advanced breast cancer: Analysis of population-based cohort with external validation
Xiangdi Meng, Furong Hao, Zhuojun Ju, Xiaolong Chang, Yinghua Guo
Frontiers in Public Health.2022;[Epub] CrossRef

10,341 View
187 Download
21 Web of Science
20 Crossref

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience: Hyojung Park, Dongryul Oh, Yong Chan Ahn, Hongryull Pyo, Jae Myung Noh, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim; Cancer Res Treat. 2017;49(4):880-889. Published online December 12, 2016; DOI: https://doi.org/10.4143/crt.2016.442

Abstract PDF PubReader ePub

Purpose
The optimal adjuvant therapy modality for treating pN2 non-small cell lung cancer patients has not yet been established. In this study, the authors investigated clinical outcomes following three different adjuvant therapy modalities.
Materials and Methods
From January 2006 to December 2012, 240 patients with cN0/1 disease were found to have pN2 disease following curative resection and received one of three adjuvant therapy modalities:thoracic radiation therapy (TRT) and concurrent chemotherapy (CTx) (CCRT) (group I), CCRT plus consolidation CTx (group II), and CTx alone (group III). TRT was delivered to 155 patients (groups I/II), and full dose CTxwas delivered to 172 patients either as a consolidative or a sole modality (group II/III).
Results
During 30 months of median follow-up, 44 patients died and 141 developed recurrence. The 5-year overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS), and disease-free survival (DFS) rates of all patients were 76.2%, 80.7%, 36.4%, and 29.6%, respectively. There was no difference in OS among groups. TRT (groups I/II) significantly improved LRC, full dose CTx (groups II/III) did DMFS, and CCRT plus consolidation CTx (group II) did DFS, respectively.
Conclusion
The current study could support that TRT could improve LRC and full dose CTx could improve DMFS and that CCRT plus consolidation CTx could improve DFS.

Citations

Citations to this article as recorded by

The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis
Dailong Li, Wanqiang Li, Yaqi Pang, Lu Xu, Xinhua Xu
Medicine.2022; 101(28): e29580. CrossRef
The efficacy of postoperative radiotherapy for patients with non-small cell lung cancer
Zexu Wang, Baixia Yang, Ping Zhan, Li Wang, Bing Wan
Journal of Cancer Research and Therapeutics.2022; 18(7): 1910. CrossRef

46,456 View
260 Download
3 Web of Science
2 Crossref

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma: Sung Hee Lim, Young Mog Shim, Se Hoon Park, Hong Kwan Kim, Young Soo Choi, Myung-Ju Ahn, Keunchil Park, Jae Ill Zo, Jong-Mu Sun; Cancer Res Treat. 2017;49(3):816-823. Published online November 9, 2016; DOI: https://doi.org/10.4143/crt.2016.417

Abstract PDF Supplementary Material PubReader ePub

Purpose
The optimal perioperative treatment for resectable esophageal squamous cell carcinoma (ESCC) remains controversial. We evaluated the efficacy and safety of leucovorin and 5-fluorouracil (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX) combination chemotherapies administered adjuvantly for curatively-resected, node-positive ESCC.
Materials and Methods
Patients with pathologically node-positive esophageal cancer after curative R0 resection were enrolled and randomly assigned to receive LV5FU2 or FOLFOX biweekly for up to eight cycles. The primary endpoint was disease-free survival (DFS).
Results
Between 2011 and 2015, 62 patients were randomized into the two treatment groups (32 in the LV5FU2 arm and 30 in the FOLFOX arm). The median age was 60 years and both groups had similar pathologic characteristics in tumor, nodal status, and location. Treatment completion rates were similarly high in both groups. The DFS rate at 12 months was 67% in the LV5FU2 group and 63% in the FOLFOX group with a hazard ratio of 1.3 (95% confidence interval [CI], 0.66 to 2.62). After a median follow-up period of 27 months, the median DFS was 29.6 months (95% CI, 4.9 to 54.2) in the LV5FU2 arm and 16.8 months (95% CI, 7.5 to 26.1) in the FOLFOX arm (p=0.428), respectively, while the median overall survival was not reached in either arm. Grade 3 or 4 neutropenia was more frequent in patients in the FOLFOX arm than the LV5FU2 arm (20.0% vs. 3.1%).
Conclusion
The addition of oxaliplatin (FOLFOX) did not lead to better efficacy compared to LV5FU2 chemotherapy in an adjuvant setting in node-positive ESCC patients.

Citations

Citations to this article as recorded by

Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials
Uchechukwu Love Anyaduba, Oluwatosin Qawiyy Orababa, Zion Faye, Nazia Rashid, Jason Shafrin, Gregory Reardon
Cancer Reports.2025;[Epub] CrossRef
Adjuvant chemotherapy in node‐positive patients after esophagectomy for esophageal squamous cell carcinoma
Yeong Jeong Jeon, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jong‐Mu Sun, Hong Kwan Kim
Thoracic Cancer.2023; 14(6): 624. CrossRef
Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis
Jaffer A. Ajani, Lisa Leung, Prianka Singh, Murat Kurt, Inkyu Kim, Mir-Masoud Pourrahmat, Steve Kanters
European Journal of Cancer.2022; 170: 119. CrossRef
Substrate-controlled selective acylation of quinazolinones: Access to 2-benzamido-N-formylbenzamides and 3-benzoylquinazolinones
Xianglin Yu, Peng Chen, Ling Jiang, Jun Lin, Yi Jin
Tetrahedron Letters.2022; 103: 153988. CrossRef
Catalyst-free highly regioselective hydrated ring-opening and formylation of quinazolinones
Xianglin Yu, Zhiliang Tang, Kun He, Weina Li, Jun Lin, Yi Jin
Organic & Biomolecular Chemistry.2022; 20(33): 6654. CrossRef
Clinical Trends in Management of Locally Advanced ESCC: Real-World Evidence from a Large Single-Center Cohort Study
Yeong Jeong Jeon, Junsang Yoo, Jong Ho Cho, Young Mog Shim
Cancers.2022; 14(19): 4953. CrossRef
Cardiotoxic effects induced by the use of antimetabolites in the chemotherapy of oncological diseases
Alina A. Aliab'eva, Galina S. Mal
CardioSomatics.2021; 12(3): 177. CrossRef
Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
Hiroo Imai, Ken Saijo, Keigo Komine, Yuya Yoshida, Keiju Sasaki, Asako Suzuki, Kota Ouchi, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka
Journal of Oncology.2020; 2020: 1. CrossRef
Adjuvant Therapy for Esophageal Squamous Cell Carcinoma
Jong-Mu Sun
The Korean Journal of Thoracic and Cardiovascular Surgery.2020; 53(4): 168. CrossRef
Copper-Catalyzed N-Formylation of Amines through Tandem Amination/Hydrolysis/Decarboxylation Reaction of Ethyl Bromodifluoroacetate
Xiao-Fang Li, Xing-Guo Zhang, Fan Chen, Xiao-Hong Zhang
The Journal of Organic Chemistry.2018; 83(20): 12815. CrossRef
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer
Vincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, Ron HJ Mathijssen, Marco J Bruno, Maikel P Peppelenbosch, Ernst J Kuipers, Manon CW Spaander
Cochrane Database of Systematic Reviews.2017;[Epub] CrossRef

13,976 View
279 Download
9 Web of Science
11 Crossref

First
Prev
Page of 1
Next
Last

Search